Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 741, Issue 1-2, 2012, Pages 81-88

  García Sar, Daniel ^a   Aguado, Leticia ^b   Montes Bayón, María ^a   Comendador, Miguel A ^b   Blanco González, Elisa ^a   Sanz Medel, Alfredo ^a   Sierra, Luisa María ^b  

^a Faculty of Chemistry   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Cisplatin; Comet assay; Drosophila melanogaster; G monoadduct; G G intrastrand cross link; HPLC ICP MS; IDA; NER; SMART

Indexed keywords

CISPLATIN; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA ADDUCT; DNA RECOMBINATION; DNA STRAND BREAKAGE; DROSOPHILA MELANOGASTER; ELECTROSPRAY MASS SPECTROMETRY; EXCISION REPAIR; EYE; FEMALE; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE DILUTION ASSAY; MALE; MASS SPECTROMETRY; MOSAICISM; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; SMART ASSAY; SOMATIC CELL; SOMATIC MUTATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; COMET ASSAY; DNA ADDUCTS; DNA BREAKS; DNA DAMAGE; DNA REPAIR; DROSOPHILA MELANOGASTER; MASS SPECTROMETRY; MUTATION; RADIOISOTOPE DILUTION TECHNIQUE;

DROSOPHILA MELANOGASTER; MAMMALIA;

EID: 83955162209     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.11.005     Document Type: Article

References (57)

1. Chhatwani L.E., Cabebe H.A.W. Adjuvant treatment of resected lung cancer. Proc. Am. Thorac. Soc. 2009, 6:194-200.
2. Sheth S. Current and emerging therapies for patients with advanced non-small-cell lung cancer. Am. J. Health Syst. Pharm. 2010, 67(1 Suppl. 1):9-14.
3. Ozols R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol. 2006, 33(2 Suppl. 6):3-11.
4. Einhorn L.H. Curing metastatic testicular cancer. Proc. Natl. Acad. Sci. 2002, 99(7):4592-4595.
5. Friedberg E.C., Walker G.C., Siede W., Wood R.D., Schultz R.A., Ellenberger T. DNA Repair and Mutagenesis 2006, ASM Press, Washington, D.C.
6. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987, 34:155-166.
7. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001, 478:1-21.
8. Almeida G.M., Duarte T.L., Steward W.P., Jones G.D.D. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline Comet assay. DNA Repair 2006, 5:219-225.
9. Rosell R., Taron M., Barnadas A., Scagliotti G., Sarries C., Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003, 10:297-305.
10. Chen H.Y., Shao C.J., Chen F.R., Kwan A.L., Chen Z.P. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 2010, 126(8):1944-1954.
11. Lee H.W., Choi Y.W., Han J.H., Kim J.H., Jung J.H., Jeong S.H., Kang S.Y., Choi J.H., Oh Y.T., Park K.J., Hwang S.C., Sheen S.S. Expression of excision repair cross-complementation group 1 proteins predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 2009, 65:377-382.
12. Rosell R., Cuello M., Cecere F., Santarpia M., Reguart N., Felip E., Taron M. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr. Opin. Oncol. 2006, 18:135-143.
13. Liedert B.D., Pluim J., Schellens J. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res. 2006, 34(6):e47.
14. Baskerville-Abraham I.M., Boysen G., Troutman J.M., Mutlu E., Collins L., Dekrafft K.E., Lin W., King C., Chaney S.G., Swenberg J.A. Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1. 2 intrastrand guanine-guanine adducts. Chem. Res. Toxicol. 2009, 22:905-912.
15. Hoebers F.J.P., Pluim D., Hart A.A.M. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother. Pharmacol. 2008, 61(6):1075-1081.
16. Sar D.G., Montes-Bayón M., Blanco-González E., Sanz-Medel A. Quantitative methods for studying DNA interactions with chemotherapeutic cisplatin. Trends Anal. Chem. 2010, 29(11):1390-1398.
17. 32P-postlabeling assay for DNA adducts. Nat. Protoc. 2007, 2:2772-2781.
18. Meczes E.L., Azim-Araghi A., Ottley C.J., Pearson D.G., Tilby M.J. Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA. Biochem. Pharmacol. 2005, 70:1717-1725.
19. Sar D.G., Montes Bayón M., Sierra L.M., Aguado Ortiz L., Blanco Gonzalez E., Sanz-Medel A. In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with the genotoxic damage in Drosophila melanogaster. Anal. Biol. Chem. 2008, 390:37-44.
20. Sar D.G., Montes Bayón M., Blanco Gonzalez E., Sanz-Medel A., Sierra L.M., Aguado L., Comendador M.A., Hann S., Kollesperger G. Quantitative profiling of in vivo generated cisplatin-DNA adduces using different isotope dilution strategies. Anal. Chem. 2009, 81(23):9553-9560.
21. Sar D.G., Montes Bayón M., Blanco González E., Sanz-Medel A. Speciation studies of cis-platin adducts with DNA nucleotides via elemental specific detection (P and Pt) using liquid chromatography-inductively coupled plasma-mass spectrometry and structural characterization by electrospray mass spectrometry. J. Anal. Atom. Spectrom. 2006, 21:861-868.
22. Calleja F.M.G.R., Nivard M.J.M., Eeken J.C.J. Induced mutagenic effects in the nucleotide excision repair deficient Drosophila mutant mus201D1 expressing a truncated XPG protein. Mutat. Res. 2001, 461:279-288.
23. Bilbao C., Ferreiro J.A., Comendador M.A., Sierra L.M. Influence of mus201 and mus308 mutations of Drosophila melanogaster on the genotoxicity of model chemicals in somatic cells in vivo measured with the Comet assay. Mutat. Res. 2002, 503:11-19.
24. Vogel E.W., Nivard M.J.M. Performance of 181 chemicals in a Drosophila assay predominantly monitoring interchromosomal mitotic recombination. Mutagenesis 1993, 8:57-81.
25. Tosal L., Comendador M.A., Sierra L.M. N-ethyl-N-nitrosourea predominantly induces mutations at AT base pairs in pre-meiotic gem cells of Drosophila males. Mutagenesis 1998, 13:375-380.
26. Vogel E.W., Barbin A., Nivard M.J.M., Snack H.F., Waters M.D., Lohman P.H.M. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents. Mutat. Res. 1998, 400:509-540.
27. Tice R.R., Agurell E., Anderson D., Burlison B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/Comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
28. Collins A.R. The Comet assay for DNA damage and repair, principles, applications and limitations. Mol. Biotechnol. 2004, 26:249-261.
29. Graf U., Frei H., Kagi A., Katz A.J., Würgler F.E. Thirty compounds tested in the Drosophila wing spot test. Mutat. Res. 1989, 222:359-373.
30. Vogel E.W., Nivard M.J.M. A novel method for the parallel monitoring of mitotic recombination and clastogenicity in somatic cells in vivo. Mutat. Res. 1999, 431:141-153.
31. Vogel E.W., Nivard M.J.M. Parallel monitoring of mitotic recombination, clastogenicity and teratogenic effects in eye tissue of Drosophila. Mutat. Res. 2000, 455:141-153.
32. + SMART is a useful tool for the evaluation of pesticides. Mutagenesis 1994, 9(4):341-346.
33. Ferreiro J.A., Sierra L.M., Comendador M.A. Methodological aspects of the white-ivory system assay of Drosophila melanogaster in relation with genetoxicity testing. Mutat. Res. 1995, 335:151-161.
34. Selby P.B., Olson W.H. Methods and criteria for deciding whether specific-locus mutation-rate data in mice indicate a positive, negative, or inconclusive result. Mutat. Res. 1981, 83(3):403-418.
35. Frei H., Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila indicate a positive, negative, or inconclusive result. Mutat. Res. 1988, 203:297-308.
36. Olive P.L., Banath J.P., Durand R.E. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal-cells measured using the Comet assay. Radiat. Res. 1990, 122(1):86-94.
37. Pastink A., Vreeken C., Nivard M.J.M. Sequence-analysis of N-ethyl-N-nitrosourea-induced vermilion mutations in Drosophila melanogaster. Genetics 1989, 123(1):123-129.
38. Katz A.J. Genotoxic effects of cisplatin in somatic tissue of Drosophila melanogaster. Environ. Mol. Mutagen. 1987, 10:197-203.
39. Kupiec M. Damage-induced recombination in the yeast Saccharomyces cerevisiae. Mutat. Res. 2000, 451:91-105.
40. Nowosielska A., Calmann M.A., Zdraveski Z., Essigmann J.M., Marinus M.S. Spontaneous and cisplatin-induced recombination in Escherichia coli. DNA Repair 2004, 3:719-728.
41. Dronkert M.L.G., Kanaar R. Repair of DNA interstrand crosslinks. Mutat. Res. 2001, 486:217-247.
42. McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001, 2:483-490.
43. Zheng H., Wang X., Legerski R.J., Glazer P.M., Li L. Repair of DNA interstrand crosslinks: interactions between homology-dependent and homology-independent pathways. DNA Repair 2006, 5:566-574.
44. Dudás A., Chovanec M. DNA double-strand break repair by homologous recombination. Mutat. Res. 2004, 566:131-167.
45. Cizeau J., Decoville M., Leng M., Locker D. Deletions induced in the white and vermilion genes of Drosophila melanogaster by the antitumor drug cis-dichlorodiammineplatinum (II). Mutat. Res. 1994, 311:31-38.
46. Niedernhofer L.J., Lalai A.S., Hoeijmakers J.H.J. Fanconi anemia (cross) linked to DNA repair. Cell 2005, 123:1191-1198.
47. Olas B., Wachowicz B., Majsterek I., Blasiak J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs 2005, 16:659-665.
48. Zamorano-Ponce E., Fernández J., Vargas G., Rivera P., Carballo M.A. Protective activity of cedron (Aloysia triphylla) infusion over genetic damage induced by cisplatin evaluated by the Comet assay technique. Toxicol. Lett. 2004, 152:85-90.
49. Jirsova K., Mandys V., Gispen W.H., Bär P.R. Cisplatin-induced apoptosis in cultures of human Schwann cells. Neurosci. Lett. 2006, 392:22-26.
50. Kopjar N., Garaj-Vrhovac V., Milas I. Assessment of chemotherapy-induced DNA damage in peripheral blood leukocytes of cancer patients using the alkaline Comet assay. Teratog. Carcinog. Mutagen. 2002, 22:13-30.
51. Pfuhler S., Wolf H.U. Detection of DNA-crosslinking agents with the alkaline Comet assay. Environ. Mol. Mutagen. 1996, 27(3):196-201.
52. Shimabukuro F., Neto C.F., Sanches J.A., Gattás G.J.F. DNA damage and repair in leukocytes of melanoma patients exposed in vitro to cisplatin. Melanoma Res. 2011, 21(2):99-105.
53. Sar D.G., Montes-Bayón M., Blanco-González E., Sierra L.M., Sanz-Medel A. Selenomethionine reduces cisplatin induced nephrotoxicity in vivo by reducing the formation of cisplatin-DNA adducts. Chem. Res. Toxicol. 2011, 24(6):896-904.
54. Harrington C.F., Le Pla R.C., Jones G.D.D. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Chem. Res. Toxicol. 2010, 23(8):1313-1321.
55. Zayed A., Sharp B., Reid H. The determination of Pt-adduct formation and repair in human cancer cells using high resolution sector field ICP-MS. European Winter Conference on Plasma Spectrochemistry 2009.
56. Dzagnidze A., Katsarava Z., Makhalova J., Liedert B., Yoon M.-S., Kaube H., Limmroth V., Thomale J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 2007, 27(35):9451-9457.
57. Buschfort-Papewalis C., Moritz T., Liedert B., Thomale J. Down-regulation of DNA repair in human CD34+ progenitor cells corresponds to increased drug sensitivity and apoptotic response. Blood 2002, 100:845-853.